

EACR

European Association  
for Cancer Research

CONFERENCES

[www.eacr.org](http://www.eacr.org)

EACR Conference

# Persister Cells: from Bacteria to Cancer

18-20 March 2025 | Lyon, France

**Scientific Programme Committee**

Yaara Oren      Caroline Robert  
Ultan McDermott      Mariangela Russo

Scan the QR code to access online conference  
resources, including speaker and poster abstracts

[eacr.org/conference/persistercells2025](http://eacr.org/conference/persistercells2025)





# Save the date

[eacr.org/conference](https://eacr.org/conference)



EACR Conference

**DEFENCE IS THE BEST ATTACK**  
Immuno-Oncology Breakthroughs

**Barcelona**, Spain

13 - 15 May 2025

European Association for Cancer Research

**EARLY CAREER**  
RESEARCHERS' CONFERENCE

**Virtual event**

24 - 25 June 2025

EACR Conference

**GOODBYE FLAT BIOLOGY:**  
ex vivo to in vivo models of cancer

**Essen**, Germany

23 - 25 September 2025

EACR Conference

**CANCER NEUROSCIENCE**

**Bilbao**, Spain

14 - 16 October 2025

EACR-Mark Foundation for Cancer Research Joint Conference

**THE RISE OF EARLY-ONSET CANCERS**  
Biology, Causes and Detection

**Bergamo**, Italy

11 - 13 November 2025

EACR Conference

**CANCER CELL PLASTICITY:**  
Cracking the Code of Adaptation and Survival

**Virtual event**

02 - 03 December 2025

**EACR**  
**2025**

16-19 June 2025  
Lisbon, Portugal

Join us for the EACR  
Annual Congress  
**2025.eacr.org**



# Persister Cells: from Bacteria to Cancer

Tag us   @helloeacr | Wi-Fi: "invites" Login: z522160 Password: YU6GRYpy

## Day 1 | Tuesday 18 March

From 11:30

### REGISTRATION

All posters can  
be put up

12:00-13:00

### WELCOME REFRESHMENTS

*A chance to meet fellow attendees and enjoy a light buffet*

13:00-13:10

### CONFERENCE WELCOME

#### Scientific Programme Committee

13:10-13:55

### PERSISTERS: WHERE ARE WE NOW ... AND WHERE ARE WE GOING?

Is it really possible to give a definition of persister cells?  
Our Scientific Programme Committee comes together to  
discuss the aims of the meeting and the key questions in  
the field.

### SESSION 1: NOVEL METHODOLOGIES FOR STUDYING PERSISTER CELLS

Chair: Yaara Oren

13:55-14:15

Q&A: 14:15-14:25

**Jan Michiels** VIB-KU Leuven Center for Microbiology, Belgium  
'Mechanistic Insights and Evolutionary Dynamics of  
Antibiotic Persistence in Escherichia coli'

14:25-14:35

Q&A: 14:35-14:40

**Shensi Shen** West China Hospital, P.R. China  
Proffered Paper 1: 'Cross-cancer Insights into Persister Cells  
Reveal an RNA methyltransferase Driving Immune Evasion'

14:40-14:50

### EXHIBITOR INTRODUCTIONS

*60-second intro pitches by each company*

14:50-15:20

### COFFEE BREAK, EXHIBITION & SOLO MEET-UP

*Solo travellers are invited to meet up at the EACR banner in the  
exhibition hall to connect with fellow adventurers*

15:20-15:40

Q&A: 15:40-15:50

**Yaara Oren** Tel Aviv University, Israel

'The day after the drug- investigating persister cells  
memory'

15:50-16:10

Q&A: 16:10-16:20

**Direna Alonso-Curbelo** IRB Barcelona, Spain

'Uncovering tissue-level interactions dictating tumor and  
senescent cell state persistence'



16:20-16:40

Q&A: 16:40-16:50

## PROMOCELL SYMPOSIUM

**Janina Moros** Promocell

'How to kill your fibroblasts and save the cancer stem cells in your culture'

16:50-17:10

Q&A: 17:10-17:20

**Cedric Blanpain** Université Libre de Bruxelles, Belgium

'Tumor States mediating Resistance to Chemotherapy'

17:20-17:30

## POSTER SPOTLIGHTS

*Posters 1, 15 and 33 will be presented in short 3-minute 'flash talks'*

17:30-18:15



**WELCOME RECEPTION** *with drinks and a light buffet*

18:15-19:45

## POSTER DISCUSSION SESSION 1

*Presenters of odd-numbered posters should stand by their boards.*

## Day 2 | Wednesday 19 March

08:30-09:00

## EARLY POSTER VIEWING

### SESSION 2: DECIPHERING THE PERSISTER CODE: MOLECULAR MECHANISMS

Chair: Lenka Munoz

09:00-09:20

Q&A: 09:20-09:30

**Susan Rosenberg** Baylor College of Medicine, USA

'Drugging Bacterial and Cancer Evolution'

09:30-09:40

Q&A: 09:40-09:45

**Lenka Munoz** University of Sydney, Australia

Proffered Paper 2: 'Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma'

09:45-10:05

Q&A: 10:05-10:15

**Céline Vallot** Institut Curie, France

'Investigating mechanisms of cell plasticity in breast cancers with single-cell epigenomics'

10:15-10:35

Q&A: 10:35-10:45

## THE EMBO KEYNOTE LECTURE

**Chris Marine** VIB-KU Leuven Center for Cancer Biology, Belgium

'A cell geometry-based approach to monitor and contend with cancer cell plasticity and therapy resistance in melanoma and beyond'

10:45-11:15



## COFFEE BREAK & EXHIBITION

11:15-11:35

Q&A: 11:35-11:45

**Aaron Hata** Massachusetts General Hospital, USA

'Mechanisms driving evolution of drug resistance in lung cancer'

11:45-11:55

Q&A: 11:55-12:00

**Jukka Westermarck** University of Turku, Finland

Proffered Paper 3: 'Transcriptional profiling of awakening of drug tolerant persisters (DTEPs) reveals DUSP6 as key driver of HER2i tolerance'



12:00-12:10

## POSTER SPOTLIGHTS

*Posters 42, 58 and 70 will be presented in 3-minute 'flash talks'*

---

12:10-13:00

## LUNCH & EXHIBITION

---

13:00-14:30

## POSTER DISCUSSION SESSION 2

*Presenters of even-numbered posters should stand by their boards*

## SESSION 3: EMERGING VULNERABILITIES: TARGETING PERSISTENT CELLS

Chair: Ultan McDermott

14:30-14:50

**Ultan McDermott** AstraZeneca, UK

Q&A: 14:50-15:00

'Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer'

15:00-15:10

**Olivier Calvayrac** CRCT, France

Q&A: 15:10-15:15

Proffered Paper 4: 'Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies'

15:15-15:35

**Eduard Batlle** IRB Barcelona, Spain

Q&A: 15:35-15:45

'Plasticity, therapy resistance and immune evasion in metastatic colorectal cancer'

---

15:45-16:15

## COFFEE BREAK & EXHIBITION

---

16:15-16:35

**Johannes Zuber** Institute of Molecular Pathology, Austria

Q&A: 16:35-16:45

'Unveiling persister cell vulnerabilities through in-vivo CRISPR screens'

16:45-17:05

**René Bernards** Netherlands Cancer Institute

Q&A: 17:05-17:15

'Finding vulnerabilities of drug-tolerant persisters identified through functional genetics'

17:15-18:00

## EARLY CAREER ADVICE: MANAGING THE WORK-LIFE BALANCE

*Interactive session led by the conference Chair Yaara Oren and conference speaker Shruti Bhatt, discussing the challenges of managing a healthy work-life balance as a young scientist.*

---

19:30

## OPTIONAL CONFERENCE DINNER (SOLD OUT)

*The conference dinner will be held at the atmospheric La Maison Restaurant (separate ticketed event - sold out).*



## Day 3 | Thursday 20 March

08:30-09:00

### EARLY POSTER VIEWING

---

09:00-09:20

Q&A: 09:20-09:30

### SESSION 4: PERSISTER CELLS IN THE CLINIC

Chair: Caroline Robert

**Wendy Mok** UConn Health, USA

'Targeting bacterial metabolism and defenses to eradicate antibiotic persisters'

09:30-09:50

Q&A: 09:50-10:00

**Shruti Bhatt** National University of Singapore, Singapore

'The Great Escape: From Persisters to Resistance Through Apoptotic Priming Loss in Leukemia Models'

10:00-10:10

Q&A: 10:10-10:15

**Isabel Puig** Vall d'Hebron Institute of Oncology, Spain

Proffered Paper 5: 'Proteomic and interactomic profiling to understand the complexities of colorectal cancer persistence'

---

10:15-10:45



### COFFEE BREAK & EXHIBITION

---

10:45-10:55

Q&A: 10:55-11:00

**Alessia Mira** University of Turin, Italy

Proffered Paper 6: 'Targeting oxidative metabolic vulnerabilities in sotorasib-tolerant lung cancer cells'

11:00-11:20

Q&A: 11:20-11:30

**Caroline Robert** Gustave Roussy, France

'Interactions of the Persister Cells with the tumor microenvironment'

11:30-11:50

Q&A: 11:50-12:00

**Trever Bivona** UCSF, USA

'Mechanisms of persister cell biology in lung cancer'

12:00

### SUMMARY, AWARDS AND DEPART



# Travel grants

More information about EACR grants: [eacr.org/travel-grant](http://eacr.org/travel-grant)

**EACR-Worldwide Cancer Research Travel Grants** provide funds to help early-career EACR members and researchers based in low- or middle-income economy countries to participate in our conferences.

Congratulations to the recipients of the travel grants for this conference. Each recipient received a full registration free of charge and funds to assist with travel and accommodation costs.

- **ÁNGELA MONTOTO FERNÁNDEZ** SPAIN
- **AVIEL ROSENBAUM** ISRAEL
- **ROCKY SHI** CANADA
- **SIRINYA SITTHIRAK** THAILAND
- **YQIN ZHOU** UK

worldwide  
cancer  
research

**EACR**  
European Association  
for Cancer Research

## Supporters

Our thanks to the following partners for supporting us in promoting this conference:



Molecular  
Oncology

Frontiers in  
Cell and Developmental  
Biology  
A journal by frontiers

The **FEBS**  
Journal



**frontiers**  
in Oncology



  
Life Science Alliance


We would also like to thank the following grant providers:



This activity has been supported by a grant from F. Hoffman-La Roche Ltd, which has had no control over the educational content of this activity.



# Venue and exhibitors



## PromoCell

**Website:** [promocell.com](http://promocell.com)

**Represented at the conference by:**

Janina Moros, Syeda Nasrin, Abdelwahab Bensmail

**PromoCell**<sup>®</sup>

**Symposium:** Tuesday 18 March | 16:20-16:50

**Janina Moros** Scientific Support Specialist, PromoCell

'How to kill your fibroblasts and save the cancer stem cells in your culture'

## IDEXX BioAnalytics

**Website:** [idexxbioanalytics.eu](http://idexxbioanalytics.eu)

**Represented at the conference by:**

Abdelhak Mansouri, Marilene Frey

**IDEXX BioAnalytics**

## Cancer Research Center of Lyon

**Website:** [www.crcl.fr](http://www.crcl.fr)

**Represented at the conference by:**

Quynh Chuong

**CRCL** CENTRE DE  
RECHERCHE EN  
CANCÉROLOGIE  
DE LYON



# Poster index

View abstracts when logged in at [www.eacr.org/conference/persistercells2025](http://www.eacr.org/conference/persistercells2025)

- 1 **[SPOTLIGHT]** Inherent Cellular Probabilities Drive Persistence to Cancer Immunotherapy Presented by Aviel Rosenbaum, Weizmann Institute of Science, Rehovot, ISRAEL
- 2 Unravelling Epigenetic Modifiers of Doxorubicin Resistance in Triple-Negative Breast Cancer via Epigenome-Wide Knockout Screens Presented by Elif Ayça Güvener, Koç University, İstanbul, TURKEY
- 3 Integrative Analysis of Baseline Transcriptional and Genomic Data: Insights into Treatment Response and Drug Resistance in HNSCC PDX Models Presented by Mary Kate Riley, Queen's University Belfast, Northern Ireland, UK
- 4 Global chromatin reorganization and regulation of evolutionary old genes during differentiation and cancer Presented by Benoît Aliaga, INSERM Centre de Recherches en Cancérologie de Toulouse, FRANCE
- 5 Characterization and targeting of chemotherapy-tolerant persister cells in Rhabdomyosarcoma Presented by Virginie Barbet, CRCL, Université Claude Bernard, Lyon, FRANCE
- 6 Keep lung cancer in check by targeting drug tolerant persister cells Presented by David Bracquemond, Institut de Recherche en Cancérologie de Montpellier, INSERM, FRANCE
- 7 Unveiling Cellular Diversity in Fusion-Positive Rhabdomyosarcoma: Single cell insights from Actinomycin D-Induced Transcriptional Changes Presented by Luca Bramé, DKTK, Heidelberg & Charité - Universitätsmedizin, Berlin, GERMANY
- 8 Mechanisms and heterogeneity of drug tolerant persister cells in TKI-treated lung cancer Presented by Floriane Braye, Université Paris-Saclay, Gustave Roussy, Villejuif, FRANCE
- 9 Exploiting 5FU-Induced Vulnerabilities in Colorectal Cancer Presented by Scott Monteith, Queen's University Belfast, UK
- 10 RNA Splicing in Colorectal Cancer Drug Tolerant Persisters Presented by Liliane Cabral-Fernandes, University of Toronto & University Health Network, Toronto, CANADA
- 11 Understanding Cancer Cell Survival and Regrowth Dynamics Using a 3D High-Throughput Culture Platform Presented by Ruonan Cao, University of Toronto, CANADA
- 12 Drug-tolerant persisters mediate resistance to the CHK1 inhibitor SRA737 in neuroblastoma cell lines Presented by LeAnne Carmichael, The Institute of Cancer Research, London, UK
- 13 Characterizing Enzalutamide-induced drug tolerant persister cells in prostate cancer. Presented by Jonathan Chow, University of Toronto, CANADA
- 14 Development of a persister platform to screen for novel antimicrobials to tackle chronic infections Presented by Marianne Costa, Olgram, Archamps, FRANCE
- 15 **[SPOTLIGHT]** Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma Presented by Rocky Shi, BC Cancer Research Institute & University of British Columbia, Vancouver, CANADA



- 16 Single-cell profiling of Drug-Tolerant Persisters surviving combination chemotherapy in a murine model of mammary cancer Presented by Jamie Cowles, Center for Cancer Research, Vienna, AUSTRIA
- 17 Precision therapy in high-grade serous ovarian cancer: Targeting drug-induced polyploid giant cancer cells Presented by Steven de Jong, University Medical Center Groningen, NETHERLANDS
- 18 Assessment of minimal residual disease in lung cancer patients treated with osimertinib using liquid biopsy Presented by Célia Delahaye, Cancer Research Center of Toulouse, Toulouse III Paul Sabatier University, FRANCE
- 19 Using synthetic promoters to identify and trace cells that escape therapy-induced senescence Presented by Noa Deshe, Tel Aviv University, ISRAEL
- 20 IFN- predisposes acute myeloid leukemia to therapy resistance Presented by Bianca E Silva, University of Liège, BELGIUM
- 21 Investigating drug-induced cellular memory in cancer cells Presented by Alex Eden, Tel Aviv University, ISRAEL
- 22 Navigating destiny- delineating the mechanisms allowing escape from therapy-induced senescence in cancer persister cells Presented by Itai Fabian, Tel Aviv University, ISRAEL
- 23 Modelling Drug-Tolerant Persistence in NSCLC: Insights into Tumor Heterogeneity and Oncolytic Virus Therapeutic Potential Presented by Clara Fauveau, CNRS & Transgene, Illkirch-Graffenstaden, FRANCE
- 24 Single-cell quantitative phospho-proteomic analysis of cellular heterogeneity to predict response of advanced melanoma to MAPK inhibitors. Presented by Florian Favier, Institut de Recherche en Cancérologie de Montpellier, FRANCE
- 25 Optimization of an MHC-I immunoprecipitation protocol for mass spectrometry analyses of persister-specific antigens in acute myeloid leukemia Presented by Charline Faville, University of Liège, BELGIUM
- 26 The ATR/CHK1 pathway inhibitors combined with olaparib re-treatment suppress tumor growth in olaparib-resistant high-grade serous ovarian cancer patient-derived xenograft models Presented by Arkadiusz Gajek, University of Lodz, POLAND
- 27 Investigating metabolic contributions to the drug-tolerant persister state in colorectal cancer cells Presented by Joshua Haebe, University of Toronto & Princess Margaret Cancer Centre, Toronto, CANADA
- 28 Isolating and Profiling Disseminated Tumor Cells to Target Persistent Disease in Breast Cancer Patients Presented by Bailey Harmon, Fred Hutchinson Cancer Center, Seattle, WA, USA
- 29 Exploring the role of the Phosphatidylserine/GAS6/AXL (PGAX) axis in the development of drug-tolerant persister cells in triple negative breast cancer treated with chemotherapy Presented by Inès Herrerueta, Univ Montpellier & IRCM, Montpellier, FRANCE
- 30 Treatment-induced adaptive immunosuppression in EGFR-mutant NSCLC Presented by Meija Honkanen, University of Turku, FINLAND
- 31 Unravelling specific features of melanoma cell lines resistant to targeted therapy Presented by Andela Horvat, Ruđer Bošković Institute, Zagreb, CROATIA



32 The role of SOCS1 in attenuating cancer cell persistence through sensitization to oxidative stress Presented by Subburaj Ilangumaran, Université de Sherbrooke, Québec, CANADA

33 **[SPOTLIGHT]** Investigation and therapeutic exploration of the epigenetic mechanisms underpinning the emergence of Drug-Tolerant Persister (DTP) cells in colorectal cancer Presented by Yaqin Zhou, Queen's University Belfast, UK

34 Identifying the molecular determinants of prostate cancer persister cells Presented by Oihana Iriondo Martinez de Zuazo, CIC bioGUNE, Derio, SPAIN & Ikerbasque, Basque Foundation for Science, Bilbao, SPAIN

35 DPPA3 as a key regulator of translation in slow-cycling colorectal cancer cells Presented by Peijin Jiang, Vall d'Hebron Institute of Oncology, Barcelona, SPAIN

36 Epigenetic investigation of drug-induced cellular memory Presented by Marina Khachatryan, Tel Aviv University, ISRAEL

37 *Poster withdrawn*

38 Breaking the lineage barrier - using single-cell lineage sequencing to identify the mechanisms underlying drug-induced histological transformation in non-small cell lung cancer Presented by Idan Lahat, Tel Aviv University, ISRAEL

39 Tracking early mechanisms of adaptation to 1L/2L therapies at single cell level in KRAS G12C mutant non-small cell lung cancer models. Presented by Alice Lallo, Novartis Pharma AG, Basel, SWITZERLAND

40 NRG1-secretory EMT Fuels ERBB3 Axis Activation in Resistance to EGFR Inhibitors Presented by Mattia Lauriola, University of Bologna, ITALY

41 Mapping the Super-Enhancers Landscape of Acute Myeloid Leukemia (AML) Persister Cells in Response to Aurora-Kinases Inhibitors (AKIs) Targeted Therapy Presented by Yam Levin-Fisher, Tel Aviv University, ISRAEL

42 **[SPOTLIGHT]** It takes two to cargo: imaging of MAPK dynamics reveals endocytic regulation of pulsatile signalling and network re-wiring in response to targeted therapy in EGFR-mutant non-small cell lung cancer. Presented by Alix Le Marois, The Francis Crick Institute, London, UK

43 Decoding drug-tolerant persisters in neuroblastoma: insights into resistance to DDR inhibitors. Presented by Valeria Elisa Marotta, The Institute of Cancer Research, London, UK

44 3D culture platforms to quantify drug tolerant cell resistance and regrowth heterogeneity in pancreatic ductal adenocarcinoma patient derived organoids Presented by Alison McGuigan, University of Toronto, CANADA

45 PRC2 and MYC Pathways Along with Fibroblast Stromal Populations Drive Fetal Conversion in Drug-Tolerant Persister Cells Presented by Ángela Montoto, HMRI, Barcelona, SPAIN

46 How to kill your fibroblasts and save the cancer stem cells in your culture Presented by Janina Moros, PromoCell GmbH, Heidelberg, GERMANY

47 Unveiling the role of HIVEP2 in chemotherapy resistance and cancer persistence Presented by Alex Mur Espinosa, Vall d'Hebron Institute of Oncology, Barcelona, SPAIN

48 FAP-high CAFs promote the formation of drug-tolerant persisters in ovarian cancer Presented by Sau Ni Ng, University of Toronto, CANADA



- 49 The role of tumor transcriptional variability in evading CD8<sup>+</sup> T cells Presented by Raymond Ng, University of Pennsylvania, Philadelphia, PA, USA
- 50 Transcriptomic analysis of treatment-persistent residual disease in BRAF-mutant lung adenocarcinoma Presented by Constance Nicq, Univ Lyon, Claude Bernard Lyon, FRANCE
- 51 Identifying targetable metabolic adaptations in drug tolerant BRAFV600E mutant Non-Small Cell Lung Cancer Presented by Marie-Julie Nokin, GIGA-University of Liège, BELGIUM
- 52 Identifying and Characterizing Drug-Tolerant Subpopulations in Pancreatic Ductal Adenocarcinoma using a High-Throughput In Vitro Model Presented by Michelle Nurse, University of Toronto, CANADA
- 53 First-in-class TET2 small drug allosteric activator to fight cancer persistence Presented by Héctor García Palmer, Vall d'Hebron Institute of Oncology, Barcelona, SPAIN
- 54 Epigenetic Dysregulation of Long Non-coding RNAs in Glioblastoma and Glioblastoma Stem Cells Presented by Rajendra Pangeni, Nova Southeastern University, Florida, USA
- 55 CRISPR screen identifies MCT1 as responsible for resistance to SMAD3 inhibition in cancer Presented by Rémy Pedoux, University of Rennes, FRANCE
- 56 Targeting Drug-Tolerant Persister cells vulnerabilities in Gastric Cancer Presented by Elisabetta Puliga, Candiolo Cancer Institute & University of Turin, ITALY
- 57 SNORD104-INDUCED RIBOSOMAL RNA 2'OME CONTRIBUTES TO CRIZOTINIB RESISTANCE IN ALK-TRANSLOCATED LUNG CANCER Presented by Julie Radermecker, Centre de Recherche en Cancérologie de Lyon, FRANCE
- 58 **[SPOTLIGHT]** From Bench to Bedside: Targeting RRM2 -Driven dNTP Metabolism to Overcome GBM Plasticity and Chemoresistance Presented by Atique Ahmed, Northwestern University, Chicago, IL, USA
- 59 Deciphering the Metastatic Potential of Drug-Tolerant Persisters in Colorectal Cancer Presented by Sumaiyah Rehman, Princess Margaret Cancer Centre, University Health Network, Toronto, CANADA
- 60 Spatiotemporal organization of residual disease in BRCA1;p53-deficient mouse mammary tumors Presented by Sven Rottenberg, University of Bern, SWITZERLAND
- 61 Autophagy mechanisms in colorectal cancer persistence and therapeutic opportunities Presented by Cándida Salvans, Vall d'Hebron Institute of Oncology, Barcelona, SPAIN
- 62 Drug Persistence to Resistance Evolution Analysis in Human Leukemia Reveals Diverse Leukemia-Initiating Cell Phenotypes. Presented by Debanjan Singha Roy, Tel Aviv University, ISRAEL
- 63 The intratumoral microbiome in cholangiocarcinoma associated chemotherapeutic resistance Presented by Sirinya Sitthirak, Cholangiocarcinoma Research Institute & Khon Kaen University, THAILAND
- 64 Targeting the DNA damage response in colorectal cancer persister cells impairs the emergence of resistance to targeted therapies Presented by Alberto Sogari, University of Torino & IFOM ETS – The AIRC Institute of Molecular Oncology, Milano, ITALY
- 65 BIM Serine 87 phosphorylation mediates resistance to EGFR-targeted therapy in EGFR-mutant lung cancer Presented by Zejia Song, University of Turku, FINLAND



66 Targeting Drug-Tolerant Persister Cells by Inhibiting P-Glycoprotein to Prevent Therapy Resistance Presented by Gergely Szakacs, Medical University of Vienna, AUSTRIA & Hungarian Research Network/Institute of Molecular Life Sciences, Budapest, HUNGARY

67 Regulation of YAP activity upon EGFR-targeted therapy in EGFR-mutant lung cancer Presented by Mari Tienhaara, University of Turku, FINLAND

68 Deciphering Mechanisms to Target Drug-Tolerant Persister Cells in Colorectal Cancer Presented by Lucrezia Tondo, German Cancer Research Center (DKFZ), Heidelberg & University Medical Center Mannheim, GERMANY

69 Unravelling the non-genetic mechanisms of drug resistance in cutaneous melanoma Presented by Laura Torres Ribas, Germans Trias i Pujol Health Science Research Institute (IGTP), Badalona, Catalonia, SPAIN

70 **[SPOTLIGHT]** Translation reprogramming in BRAF V600 mutant melanoma persister cells modulates the tumor microenvironment through MIF secretion Presented by Laura Soumoy, Institut Gustave Roussy, Villejuif, FRANCE

71 Multiparametric longitudinal single-cell analysis of DTPs in pancreatic neuroendocrine tumors reveal drug-tolerant cells clusters with distinctive traits and trajectories in response to therapy stress Presented by Camilla Petra Ullmann, Institut for Tissue Medicine and Pathology, Bern, SWITZERLAND

72 Dissecting the clonal evolution of resistance to KRAS inhibitors through genetic barcoding and scRNAseq Presented by Christian Umkehrer, Boehringer Ingelheim, Vienna, AUSTRIA

73 Multiplexed Clonal Enrichment Reveals Diverse Mechanisms of Cancer Therapy Tolerance Presented by Robert Vander Velde, University of Pennsylvania, Philadelphia, PA, USA

74 Lipid metabolism reprogramming supports escape to anti-EGFR therapy in head and neck cancers Presented by Julie Vignau, UCLouvain, Brussels, BELGIUM

75 NRF2-driven persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition Presented by Wei Zhang, The University of Manchester, UK, & Turku Bioscience Centre, FINLAND

76 Drug-Tolerant Persisters Drive Treatment Resistance in AML through Dynamic Regulation of Apoptotic Priming Presented by Ankit Jana, National University of Singapore, SINGAPORE



## Notes

---







## Notes

---







**Communication.  
Collaboration.  
Community.**

# EACR

European Association  
for Cancer Research



**NOT A MEMBER  
YET? JOIN NOW**

**Apply for funding  
to develop your  
research &  
expand  
your  
horizons**



**Benefit from  
member  
registration  
rates at EACR  
events**

**Join our online  
networking  
events**



**Build new  
connections  
with our 'Find a  
Collaborator'  
tool**

**Search  
the EACR  
Member  
Network  
and message  
other members**



**Share your  
perspective: write  
for The Cancer  
Researcher  
magazine**

**Access  
our free  
expert  
webinars on  
research &  
careers**



**Stay informed  
with regular  
updates on  
news, jobs &  
conferences**

**Volunteer for  
our Ambassador  
Programme or  
committees**



# EACR onsite team



**Chris Iliffe**  
Conference Officer



**Kathryn Wass**  
Programmes Manager



**Alexandra Boitor**  
Scientific Officer



**Catherine Burns**  
Membership Coordinator


## Conference dinner

### Optional ticketed event, Wednesday 19 March, 19:30 (SOLD OUT)

The conference dinner will take place on the second night of the meeting. It will be an excellent opportunity for participants and speakers to get to know each other in a relaxed and informal environment. Smart dress required.

It is important that you bring your participant badge with you to La Maison for entry to the restaurant otherwise you may not be permitted entry. Please do not arrive at the venue any earlier than 19:00pm.

La Maison Restaurant, 4 Rue Jonas Salk, 69007 Lyon





## EACR Industry Partners

The European Association for Cancer Research gratefully acknowledges its Industry Partners, who offer ongoing support to the EACR and provide the means for the association to develop important initiatives.

